Thomas Marron, MD, PhD, on Research Design for the Neoantigen Peptide Vaccine, PGV-001

Video

Marron detailed the research process for a phase 1 trial of PGV-001 presented virtually at the American Association for Cancer Research Annual Meeting 2021.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork® at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 about research methods for investigating the neoantigen peptide vaccine, PGV-001.

Transcription:

The neoantigen peptide vaccine PGV-001 uses the Open Vax platform, which is a computational pipeline that basically takes whole-exome sequencing and bulk RNA sequencing from tumors that have been typically excised for the majority of patients. We sequence the tumor DNA and RNA, we also do germline DNA sequencing, and we identify mutations that are unique to the tumor. We then confirm expression using the bulk RNA sequencing. And then once we have a list of potential neoantigens in the tumor, we use the patient’s specific HLA type to predict which of those neoantigens might be most immunogenic [or] most likely for the immune system to be able to recognize based on that patient’s unique immune characteristics. And then, once we identify the top 10 neoantigens initially—we actually identified the top 20, and then based on the synthesis capabilities of our partner that synthesized the peptides over in Germany—we vaccinated patients with those peptides.

Reference:

Marron TU, Saxena M, Bhardwaj N, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB048.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
Related Content